Valneva (NASDAQ:VALN) Trading Up 7.1% – Time to Buy?

Valneva SE Sponsored ADR (NASDAQ:VALN)’s share price was up 7.1% during mid-day trading on Wednesday . The company traded as high as $6.98 and last traded at $7.0340. Approximately 32,776 shares traded hands during trading, a decline of 51% from the average session volume of 67,036 shares. The stock had previously closed at $6.57.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. TD Cowen assumed coverage on shares of Valneva in a research note on Tuesday, August 11th. They issued a “buy” rating and a $12.00 price target on the stock. Wall Street Zen upgraded shares of Valneva from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Valneva in a research note on Thursday, June 18th. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $9.30.

Valneva Stock Up 6.2%

The stock has a market capitalization of $662.33 million, a price-to-earnings ratio of -3.30 and a beta of 1.67. The company has a debt-to-equity ratio of 2.04, a current ratio of 2.16 and a quick ratio of 1.69. The business has a fifty day moving average of $5.57 and a 200 day moving average of $6.67.

Valneva (NASDAQ:VALN) last posted its earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.21). Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. The business had revenue of $39.37 million during the quarter, compared to analysts’ expectations of $44.17 million. As a group, equities analysts predict that Valneva SE Sponsored ADR will post -1.27 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Marex Group plc purchased a new stake in shares of Valneva in the 2nd quarter valued at approximately $64,000. XTX Topco Ltd acquired a new stake in shares of Valneva in the fourth quarter valued at $94,000. Finally, JPMorgan Chase & Co. acquired a new position in Valneva in the 3rd quarter valued at about $124,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.